Related Experiment Videos
[3H]MK-801 binding in Alzheimer's disease
M M Mouradian1, P C Contreras, J B Monahan
1Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20892.
Neuroscience Letters
|November 11, 1988
Summary
Researchers investigated N-methyl-D-aspartate (NMDA) receptor binding sites in Alzheimer's disease brains. No significant differences in [3H]MK-801 binding were found between patients and controls, suggesting altered glutamatergic neurotransmission is not due to NMDA receptor MK-801 sites.
Area of Science:
- Neuroscience
- Neuropathology
- Pharmacology
Background:
- Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline.
- Glutamatergic neurotransmission, involving N-methyl-D-aspartate (NMDA) receptors, is implicated in AD pathogenesis.
- The MK-801 binding site on the NMDA receptor complex is a key target for studying receptor function.
Purpose of the Study:
- To quantify the density of [3H]MK-801 binding sites in various cortical regions of postmortem Alzheimer's disease brains.
- To compare these densities with age-matched control brains to identify potential alterations in NMDA receptor function in AD.
- To investigate whether changes in glutamatergic neurotransmission in AD involve the MK-801 recognition site.
Main Methods:
- Postmortem brain tissue from Alzheimer's patients and age-matched controls was used.
- Brain homogenates from different cortical regions were prepared.
- Radioligand binding assays using [3H]MK-801 were performed to measure binding site density and affinity.
Main Results:
- The highest density of [3H]MK-801 binding sites was consistently observed in the temporal pole (Brodmann area 38) in both Alzheimer's patients and control groups.
- No statistically significant differences in binding density or affinity constants were detected between Alzheimer's patients and controls across the studied cortical regions.
- These findings indicate no substantial alterations at the MK-801 recognition site on the NMDA receptor complex in the brains of Alzheimer's disease patients.
Conclusions:
- The glutamatergic system's involvement in Alzheimer's disease does not appear to be mediated by changes in the MK-801 binding site on the NMDA receptor.
- Further research is needed to explore other components of the glutamatergic system or alternative neurotransmitter pathways in AD.
- These results contribute to understanding the complex neurochemical alterations in Alzheimer's disease.